Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Aims: To investigate whether the degree of albuminuria reduction observed in the ALTITUDE trial is associated with renal and cardiovascular protection, and secondly, whether the reduction in albuminuria was too small to afford clinical benefit. Methods: In a post hoc analysis of the ALTITUDE trial in 8561 patients with type 2 diabetes and chronic kidney disease or cardiovascular disease we examined the effect of albuminuria changes at 6 months on renal and cardiovascular outcomes using C ox proportional hazard regression. Results: The median change in albuminuria in the first 6 months in the aliskiren arm of the trial was −12% (25th to 75th percentile: −48.7_to_ +41.9%) and 0.0% (25th to 75th percentile: −40.2_to_55%) in the placebo arm. Changes in albuminuria in the first 6 months were linearly associated with renal and cardiovascular endpoints: a >30% reduction in albuminuria in the first 6 months was associated with a 62% reduction in renal risk and a 25% reduction in cardiovascular risk compared with an increase in albuminuria. The association between changes at 6 months in albuminuria and renal or cardiovascular endpoints was similar in the two treatment groups (p for interaction >0.1 for both endpoints). Conclusions: The addition of aliskiren to angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker therapy resulted in albuminuria changes that were associated with renal and cardiovascular risk changes. This did not translate into renal or cardiovascular protection because the overall reduction in albuminuria in the aliskiren arm was too small and nearly similar to that in the placebo arm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationStandards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60674-5 · Cited by 4,200 · cited 1×
“Previous studies showed no lower albuminuria threshold below which the risk between albuminuria and cardiovascular and renal outcomes did not decrease [3,26].”
ResultAlbuminuria reflects widespread vascular damage: The Steno hypothesis
Deckert, T., Feldt-Rasmussen, B., Borch-Johnsen, K., Jensen, T., & Kofoed-Enevoldsen, A. (1989) · Diabetologia · doi:10.1007/bf00285287 · Cited by 1,400
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319 · cited 2×
“The study design and principal findings have been published previously [13,19].”
BackgroundSelf-citationCombined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes
Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008121270 · Cited by 965
Self-citationStehouwer, C. D. A., Gall, M.-A., Twisk, J. W. R., Knudsen, E., Emeis, J. J., & Parving, H.-H. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1157 · Cited by 652
Self-citationMakani, H., Bangalore, S., Desouza, K. A., Shah, A., & Messerli, F. H. (2013) · BMJ · doi:10.1136/bmj.f360 · Cited by 244 · cited 1×
“Based on these trial results, doubts have been raised about the validity of albuminuria changes as an independent predictor of renal and cardiovascular protective therapy [15,16]; however, the 10–15% reduction in albuminuria observed in these trials was less than half of the 30% reduction in albuminuria observed in pr…”
Result
Research works printed but not linked: 24
- 10.2337/dc13-2036 · DOI · Paper page
- 10.7326/0003-4819-139-11-200312020-00008 · DOI · Paper page
- 10.1161/01.CIR.0000031732.78052.81 · DOI · Paper page
- 10.1111/j.1523-1755.2004.00653.x · DOI · Paper page
- 10.1007/s00125-012-2755-2 · DOI
- 10.1001/archinte.165.8.947 · DOI · Paper page
- 10.1046/j.1523-1755.2003.00033.x · DOI · Paper page
- 10.1093/eurheartj/ehr017 · DOI · Paper page
- 10.1038/ki.2014.321 · doi:10.1038/ki.2014.321
- 10.2337/dc08-s248 · DOI
- 10.7326/0003-4819-159-11-201312030-00009 · DOI · Paper page
- 10.1056/NEJMoa011303 · DOI · Paper page
- 10.1093/ndt/gfn721 · DOI · Paper page
- 10.1681/ASN.2006050445 · DOI · Paper page
- 10.1161/01.CIR.0000139860.33974.28 · DOI · Paper page
- 10.1093/ndt/gft249 · DOI
- 10.1681/ASN.2008070730 · DOI · Paper page
- 10.1681/ASN.2008060655 · DOI · Paper page
- 10.1053/j.ajkd.2012.06.017 · DOI
- 10.1053/j.ajkd.2004.10.019 · DOI · Paper page
- 10.1016/0272-6386(95)90058-6 · doi:10.1016/0272-6386(95)90058-6
- 10.1046/j.1523-1755.1998.00905.x · DOI · Paper page
- 10.1152/ajprenal.00069.2006 · DOI
- 10.1152/ajprenal.2001.280.4.F562 · DOI · Paper page
Cited by
Heerspink, H. J. L., Parving, H.-H., Andress, D. L., Bakris, G., Correa-Rotter, R., Hou, F.-F., Kitzman, D. W., Kohan, D., Makino, H., McMurray, J. J. V., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30772-x · Cited by 628
Self-citationHeerspink, H. J. L., Greene, T., Tighiouart, H., Gansevoort, R. T., Coresh, J., Simon, A. L., Chan, T. M., Hou, F. F., Lewis, J. B., Locatelli, F., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30314-0 · Cited by 397
Self-citationRenoprotective effects of sodium-glucose cotransporter-2 inhibitors
Heerspink, H. J. L., Kosiborod, M., Inzucchi, S. E., & Cherney, D. Z. I. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.027 · Cited by 393
Self-citationCherney, D. Z. I., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., von Eynatten, M., & Wanner, C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30182-1 · Cited by 383
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
Mosenzon, O., Leibowitz, G., Bhatt, D. L., Cahn, A., Hirshberg, B., Wei, C., Im, K., Rozenberg, A., Yanuv, I., Stahre, C., et al. (2017) · Diabetes Care · doi:10.2337/dc16-0621 · Cited by 268
Metadata
- Authors
- Heerspink, H. J. L., Ninomiya, T., Persson, F., Brenner, B. M., Brunel, P., Chaturvedi, N., Desai, A. S., Haffner, S. M., Mcmurray, J. J. V., Solomon, S. D., Pfeffer, M. A., Parving, H. ‐., & de Zeeuw, D.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-01-13
- Volume
- 18
- Issue
- 2
- Pages
- 169-177
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1945685354
- Cited by
- 57
- References
- 9
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Novartis Pharmaceuticals Corporation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.